ALK upgrades guidance after positive Q3 report

The allergy group now expects organic revenue growth of 11-12 percent compared to previous expectations of 10-12 percent.

Photo: ALK / PR

ALK has done better than antcipated on both its top and bottom lines, boosted by surpringsly strong sales of allergy drugs.

Tablet sales amounted to DKK 398m (USD 61.4m) against the the average analyst estimate of DKK 372m (USD 57.4m) collected by ALK.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs